Literature DB >> 31095956

Optic Disc Pit Maculopathy: New Perspectives on the Natural History.

Edward Bloch1, Odysseas Georgiadis2, Marko Lukic2, Lyndon da Cruz3.   

Abstract

PURPOSE: To investigate the natural history of optic disc pit maculopathy and explore the associations between demographic, anatomic, and functional characteristics.
DESIGN: Retrospective, comparative case series.
METHODS: This was a single-center medical record review of previously untreated optic disc pit maculopathy. Baseline data of visual function, demographics, and pit physiognomy were collected, and further subgroup analysis was undertaken on patients with long-term follow-up, according to whether they were monitored or received surgical intervention. LogMAR visual acuity was the primary outcome measure, and anatomic characteristics were reported where available.
RESULTS: Eighty-seven patients were identified with a new presentation of optic disc pit maculopathy. No demographic or pit features were correlated with vision at baseline. In 51 patients with available optical coherence tomography data, only the presence of subretinal fluid at baseline was associated with poorer visual acuity (P < .001). Fifty-two patients who were monitored without treatment had available long-term follow-up data. The mean change in visual acuity in this group was 0.01, with 77% maintaining visual acuity ≤0.30. Twenty-seven patients underwent surgery and showed significant postoperative improvement in vision (P < .001), with 59% achieving an acuity ≤0.30. Duration of postoperative follow-up was associated with better visual acuity (P = .007).
CONCLUSION: Many patients with optic disc pit maculopathy maintain good long-term visual acuity and may demonstrate resolution of subretinal fluid in the absence of surgical intervention. There may be evidence to support delaying surgical treatment until visual deterioration is observed because of the potential stability or spontaneous improvement of the condition, the high rate of reoperation, and the long-term positive outcomes of deferred intervention.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31095956     DOI: 10.1016/j.ajo.2019.05.010

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Intraoperative optical coherence tomography findings during surgery for optic disc pit-associated maculopathy.

Authors:  Hyun Goo Kang; Sung Eun Park; Eun Young Choi; Sung Chul Lee; Min Kim
Journal:  Int J Ophthalmol       Date:  2020-04-18       Impact factor: 1.779

2.  AN ASSOCIATION BETWEEN STELLATE NONHEREDITARY IDIOPATHIC FOVEOMACULAR RETINOSCHISIS, PERIPHERAL RETINOSCHISIS, AND POSTERIOR HYALOID ATTACHMENT.

Authors:  Edward Bloch; Blanca Flores-Sánchez; Odysseas Georgiadis; Venki Sundaram; Zubin Saihan; Omar A Mahroo; Andrew R Webster; Lyndon da Cruz
Journal:  Retina       Date:  2021-11-01       Impact factor: 4.256

3.  Let-7, Lin28 and Hmga2 Expression in Ciliary Epithelium and Retinal Progenitor Cells.

Authors:  Lorena Teixeira Frasson; Barbara Dalmaso; Priscilla Sayami Akamine; Edna Teruko Kimura; Dânia Emi Hamassaki; Carolina Beltrame Del Debbio
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-03-01       Impact factor: 4.799

4.  Double trouble: Optic disc pit maculopathy in advanced glaucoma.

Authors:  Rinal Pandit; Deepanshu Agarwal; Dhaivat Shah
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

5.  Juxtapapillary retinochoroidal coloboma presenting with macular retinoschisis.

Authors:  Raj S Hirawat; C K Nagesha; M Arthi
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

6.  Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide.

Authors:  Susan Ruyu Qi; Eunice You; Melanie Hebert; Ali Dirani
Journal:  Int Med Case Rep J       Date:  2021-05-26

7.  Treatment outcomes of optic disc pit maculopathy over two decades.

Authors:  Avadhesh Oli; Divya Balakrishnan
Journal:  Ther Adv Ophthalmol       Date:  2021-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.